Compare MKC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKC | NBIX |
|---|---|---|
| Founded | 1889 | 1992 |
| Country | United States | United States |
| Employees | 14100 | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 13.2B |
| IPO Year | N/A | 1996 |
| Metric | MKC | NBIX |
|---|---|---|
| Price | $46.06 | $158.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | $67.00 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 3.3M | 1.2M |
| Earning Date | 03-31-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $16.24 | $24.73 |
| Revenue Next Year | $3.71 | $13.14 |
| P/E Ratio | ★ $23.90 | $83.53 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $44.82 | $117.84 |
| 52 Week High | $78.03 | $162.39 |
| Indicator | MKC | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 31.46 | 75.63 |
| Support Level | N/A | $125.54 |
| Resistance Level | $69.16 | $158.92 |
| Average True Range (ATR) | 1.37 | 4.50 |
| MACD | -0.16 | 2.55 |
| Stochastic Oscillator | 16.88 | 89.50 |
In its 135-plus-year history, McCormick has become the leading global manufacturer of spices, herbs, extracts, seasonings, and other flavorings. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and Cholula. This mix will be complemented by the pending addition of Unilever's food brands, primarily Knorr cooking aids and Hellmann's mayonnaise. After the deal close, the combined business is slated to generate 70% of sales from consumers and 30% from restaurants and other packaged food and beverage manufacturers. Around 40% of sales are slated to come from faster-growing emerging markets, with Europe (23%) and North America (36%) accounting for the remainder.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.